Pharmaceutical and biotechnological manufacturers face increasing pressures to effectively bring innovative therapies to the global market while at the same time, meeting local evidence requirements. As a result, remaining close to the evolving payer and health technology assessment (HTA) landscape is critical. Insights on these complex environments are needed to inform clinical development and health economics and outcomes research (HEOR) evidence generation strategies in the pipeline stages and throughout the life cycle of new specialty and biotechnology products.
This webinar will have particular focus on the US, Canada and Germany in order to:
1) Describe current and anticipated trends in access for new specialty and biotechnology products
2) Review the evidence guidelines set by specific payers/HTA bodies
3) Demonstrate best practices for developing access strategies and value propositions
Trent McLaughlin, BSc (Pharm), PhD, Vice-President, Xcenda
Trent McLaughlin, BSc(Pharm), PhD, is Vice President, Scientific Client Strategies for Xcenda. He leads a team of consultants who partner with Pharmaceutical and biotech manufacturers on strategic engagements such as health economics and outcomes research, global market access strategy, comparative effectiveness research, and economic modeling.
Dr. McLaughlin has over 15 years of health economic and outcomes research (HEOR) experience, both as a consultant as well as a senior member of Pharmaceutical manufacturers’ global HEOR departments. Dr. McLaughlin has authored over 50 peer-reviewed publications in a wide variety of therapeutic areas, including Alzheimer’s disease, asthma, COPD, diabetes, depression, infectious disease, and oncology.
Originally from Halifax, Nova Scotia, Dr. McLaughlin received his pharmacy degree from Dalhousie University and his PhD from the University of South Carolina.Message Presenter
Marie-Josée Martel, PhD, Director, Xcenda
Marie-Josée Martel, PhD, is Director, Scientific Client Strategies at Xcenda. In this role, she leads global health economics and outcomes research (GHEOR) engagements related to comparative effectiveness and pharmacoepidemiology, and health economics. Additionally, she assists clients with the development of their global strategic initiatives related to market access.
Dr. Martel has over 12 years of experience in the Pharmaceutical industry. Prior to joining Xcenda, she was Associate Director, HEOR Oncology for a global bioPharmaceutical company where she led projects and actively contributed to global strategies supporting pipeline assets. As part of the Health Economics and Market Access team for the Canadian affiliate, she led many HEOR initiatives and developed reimbursement submissions and communications in support of key products.
Dr. Martel holds a PhD in Pharmaceutical Sciences from the Université de Montréal and also serves as adjunct faculty at the Faculty of Pharmacy, Université de Montréal.Message Presenter
Who Should Attend?
Individuals interested in global market access for specialty and biotechnology products, including professionals in:
- Clinical development
- Regulatory issues
- Medical Affairs
- Market Access
This may also be of interest to individuals in Payer and HTA organizations who deal with specialty and biotechnology products.
Xcenda is a strategic consulting firm with 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. We support global Pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, Xcenda helps manufacturers identify, demonstrate, and deliver their brand’s value proposition to key healthcare stakeholders.
Xcenda is backed by an even wider breadth of healthcare knowledge and partnerships through AmerisourceBergen Corporation (NYSE: ABC), one of the world’s largest Pharmaceutical services companies. Xcenda’s strategic consulting services support the design of patient support services and specialty distribution programs to improve product access and adherence at every stage of its life cycle.